Get the Stockscreener App
3.6715
3.69%
0.1315
Recursion Pharmaceuticals Inc stock is traded at $3.6715, with a volume of 6.91M.
It is up +3.69% in the last 24 hours and up +7.32% over the past month.
Recursion Pharmaceuticals Inc is a clinical-stage biotechnology company. The company is decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering, with the goal of radically improving the lives of patients and industrializing drug discovery. Geographically, the company operates in United States, United Kingdom, and Others. It derives maximum revenue from United States.
See More
Previous Close:
$3.54
Open:
$3.57
24h Volume:
6.91M
Relative Volume:
0.40
Market Cap:
$1.94B
Revenue:
$74.68M
Net Income/Loss:
$-644.76M
P/E Ratio:
-2.4759
EPS:
-1.4829
Net Cash Flow:
$-380.44M
1W Performance:
+8.27%
1M Performance:
+7.32%
6M Performance:
-45.94%
1Y Performance:
-34.92%
1-Day Range:
$3.56
$3.73
1-Week Range:
$3.23
$3.73
52-Week Range:
$2.80
$7.18
Recursion Pharmaceuticals Inc Stock (RXRX) Company Profile
Name
Recursion Pharmaceuticals Inc
Sector
Industry
Phone
(385) 269-0203
Address
41S RIO GRANDE STREET, SALT LAKE CITY
Compare RXRX vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RXRX
Recursion Pharmaceuticals Inc
|
3.675 | 1.87B | 74.68M | -644.76M | -380.44M | -1.4829 |
VRTX
Vertex Pharmaceuticals Inc
|
438.32 | 113.01B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
746.08 | 79.87B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
839.75 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
334.74 | 45.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
315.71 | 34.41B | 5.36B | 287.73M | 924.18M | 2.5229 |
Recursion Pharmaceuticals Inc Stock (RXRX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-17-25 | Upgrade | JP Morgan | Neutral → Overweight |
| Jul-03-25 | Resumed | Morgan Stanley | Equal-Weight |
| May-22-23 | Initiated | Morgan Stanley | Equal-Weight |
| Mar-16-23 | Initiated | Needham | Buy |
| Sep-16-22 | Initiated | KeyBanc Capital Markets | Overweight |
| Apr-18-22 | Downgrade | BofA Securities | Buy → Neutral |
| Mar-04-22 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Sep-21-21 | Initiated | Berenberg | Buy |
| May-11-21 | Initiated | BofA Securities | Buy |
| May-11-21 | Initiated | Goldman | Neutral |
| May-11-21 | Initiated | JP Morgan | Neutral |
| May-11-21 | Initiated | KeyBanc Capital Markets | Overweight |
| May-11-21 | Initiated | SVB Leerink | Outperform |
View All
Recursion Pharmaceuticals Inc Stock (RXRX) Latest News
Recursion Pharmaceuticals Inc. (RXRX) partners with Citeline to develop AI-powered ClinTech platform - MSN
Recursion Pharmaceuticals (RXRX) down 16.5% since last earnings report: Can it rebound? - MSN
Recursion Pharmaceuticals Stock (RXRX) Opinions on Upcoming Earnings and AI Developments - Quiver Quantitative
symbol__ Stock Quote Price and Forecast - CNN
Recursion And Citeline Deepen AI Trial Data Tie For RXRX Investors - Yahoo Finance
Why Recursion (RXRX) Is Up 10.8% After Deepening Citeline Partnership To Power AI-Driven Clinical Trials - Sahm
Recursion Pharmaceuticals, Inc. (RXRX) Stock Price, News, Quote & History - Yahoo! Finance Canada
RXRX|Recursion Pharmaceuticals Inc|Price:3.369|Chg%:0.09 - TradingKey
Recursion Pharmaceuticals (RXRX) stock declines while market improves: Some information for investors - MSN
Recursion Pharmaceuticals, Inc. (RXRX) stock price, news, quote and history - Yahoo Finance UK
Recursion Pharmaceuticals (RXRX) Stock Declines While Market Improves: Some Information for Investors - Yahoo Finance
Insider Sell Alert: Blake Borgeson Sells 30,000 Shares of Recurs - GuruFocus
Recursion names Vicki Goodman as CMO - MSN
Recursion to Participate in Upcoming Investor Conferences - marketscreener.com
Recursion Pharmaceuticals Inc. (RXRX) Partners with Citeline to Develop AI-Powered ClinTech Platform - Insider Monkey
Fund Flows: Is Recursion Pharmaceuticals Inc forming a double bottom2026 Snapshot & Advanced Swing Trade Entry Alerts - baoquankhu1.vn
Recursion Pharmaceuticals, Inc. (RXRX) latest stock news and headlines - au.finance.yahoo.com
Does AI Data Deal And New CMO Hire Change The Bull Case For Recursion (RXRX)? - Sahm
Recursion Pharmaceuticals (RXRX) beats stock market upswing: What investors need to know - MSN
Recursion Pharmaceuticals (RXRX) Beats Stock Market Upswing: What Investors Need to Know - Yahoo Finance
Director at Recursion (NASDAQ: RXRX) awarded 3,268 shares - Stock Titan
Expanded Citeline Data Partnership and CMO Transition Could Be A Game Changer For Recursion Pharmaceuticals (RXRX) - Yahoo Finance
A Look At Recursion Pharmaceuticals (RXRX) Valuation As Investor Narratives Diverge - Sahm
1 Beaten-Down AI Stock to Buy and 1 to Avoid - Yahoo Finance
Citeline expands partnership with Recursion for clinical trials - investing.com
Recursion Expands Strategic Partnership with Citeline to Advance Its AI-Enabled ClinTech Platform - GlobeNewswire Inc.
2 AI Healthcare Stocks to Buy Right Now - The Globe and Mail
RXRX Stock Price, Quote & Chart | RECURSION PHARMACEUTICALS-A (NASDAQ:RXRX) - ChartMill
RXRX SEC FilingsRecursion Pharmaceuticals, Inc. 10-K, 10-Q, 8-K Forms - stocktitan.net
Recursion Pharmaceuticals (RXRX) Surges 14% Ahead of Earnings - MSN
Recursion Pharmaceuticals (NASDAQ:RXRX) Rating Lowered to Sell at Wall Street Zen - MarketBeat
Recursion Pharmaceuticals stock hits 52-week low at $2.98 By Investing.com - Investing.com Australia
Recursion Pharmaceuticals Inc Stock (RXRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Recursion Pharmaceuticals Inc Stock (RXRX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Borgeson Blake | Director |
Apr 07 '26 |
Sale |
3.10 |
30,000 |
93,000 |
6,229,863 |
1.80%
0.71%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):